menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Incyte Monjuvi Data Shows Improved Survival In Follicular Lymphoma

    BUSINESSWIRE

    Incyte`s Monjuvi proves its worth in follicular lymphoma

    FIERCE PHARMA

    Incyte to Present New Tafasitamab Data at 2024 ASH Annual Meeting

    BUSINESSWIRE

    Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win

    FIERCE PHARMA

    Incyte Announces Positive Results From Tafasitamab Study In Follicular Lymphoma

    BUSINESSWIRE

    InnoCare`s Tafasitamab BLA Accepted For DLBCL Treatment In China

    BUSINESSWIRE

    Incyte Gains Development and Commercialization Rights to Tafasitamab (Monjuvi®)

    BUSINESSWIRE

    InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program

    BUSINESSWIRE

    China’s CDE grants approval for InnoCare’s NHL therapy trial

    CLINICALTRIALSARENA

    InnoCare Announces Approval to Conduct a Ph II Clinical Trial of Orelabrutinib

    BUSINESSWIRE

    MorphoSys to Share New Data on Pelabresib and Monjuvi in 14 Presentations at ASH

    ACCESSWIRE

    MorphoSys to Share New Data on Pelabresib and Monjuvi®

    PRESS RELEASE

    MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales

    ACCESSWIRE

    MorphoSys shows Data from L-MIND Suggesting Response to Treatment with Monjuvi

    BUSINESSWIRE

    InnoCare Announces 1st Patient Dosed in PII Trial of Tafasitamab & Lenalidomide

    BUSINESSWIRE

    InnoCare`s BLA for Tafasitamab in Combination with Lenalidomide got Acceptence

    BUSINESSWIRE

    MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

    BUSINESSWIRE

    Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi

    BUSINESSWIRE

    MorphoSys and Incyte Announce Additional Real-World Evidence Results RE-MIND2

    BUSINESSWIRE

    MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study

    BUSINESSWIRE

    MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months

    MORPHOSYS

    Specialised Therapeutics Enters into a New Supply and Distribution Agreement

    PRNEWSWIRE

    Incyte`s Minjuvi (tafasitamab) Receives Approval in Europe

    EMA

    Incyte and MorphoSys announce European Commission clearance of Minjuvi ®

    BUSINESSWIRE

    Morphosys Us Inc`s Biological Tafasitamab-Cxix Receives Approval In US

    FDA

    Health Canada accepts Incyte & MorphoSys’ NDS for tafasitamab in combo

    PHARMABIZ

    Incyte and MorphoSys Announce by Health Canada of the NDA for Tafasitamab

    BIOSPACE

    Xencor, MorphoSys and Incyte Enter into Global Development Collaboration

    BIOSPACE

    National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix)

    BUSINESSWIRE

    FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T

    ENDPTS

    In a first, MorphoSys, Incyte win Monjuvi FDA nod in lymphoma

    FIERCE PHARMA

    FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide

    BUSINESSWIRE

    Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi®

    BUSINESSWIRE

    EMA starts review of MorphoSys’ tafasitamab for lymphoma

    PMLIVE

    Incyte & MorphoSys Announce the Validation of European Marketing for Tafasitamab

    BUSINESSWIRE

    MorphoSys & Incyte Announce Antitrust Clearance of Global Collab for Tafasitamab

    YAHOO

    MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.

    PRESS RELEASE

    MorphoSys & Incyte Sign Global Collab and License Agreement for Tafasitamab

    PRESS RELEASE

    Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine

    REUTERS

    Morphosys to boost size of tafasitamab drug trial on encouraging interim data

    REUTERS

    Morphosys to boost size of tafasitamab drug trial on encouraging interim data

    REUTERS

    Morphosys to boost size of tafasitamab drug trial on encouraging interim data

    REUTERS

    MorphoSys to submit MAA for tafasitamab to European Medicines Agency

    PHARMABIZ

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.